Last update 01 Nov 2024

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL

Private Company|
Romania

Overview

Tags

Neoplasms
Nervous System Diseases
Other Diseases
Therapeutic radiopharmaceuticals
Peptide Conjugate Radionuclide
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms4
Endocrinology and Metabolic Disease2
Nervous System Diseases2
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Therapeutic radiopharmaceuticals3
Peptide Conjugate Radionuclide2
Radionuclide Drug Conjugates (RDC)1
Small molecule drug1
Top 5 TargetCount
σ1 receptor x σ2 receptor1
SSTR(Somatostatin receptor)1
PSMA(Prostate-specific membrane antigen)1

Related

6
Drugs associated with Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Lutetium (177Lu) edotreotide
Target
SSTR
Mechanism
SSTR antagonists
Active Org.
ITM Isotopen Technologien München AG [+3]
Originator Org.
Universitätsspital BaselUniversitätsspital Basel
Active Indication
Neuroendocrine neoplasm of lung [+11]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
Lutetium-177-PSMA-I&T
Target
PSMA
Mechanism
PSMA inhibitors
Active Org.
Radboud University Medical CenterRadboud University Medical Center [+2]
Originator Org.
Radboud University NijmegenRadboud University Nijmegen
Active Indication
Prostatic Cancer [+3]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Avidin-biotin-Dota-90Y(Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori)
Target-
Mechanism-
Active Org.
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Originator Org.
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Active Indication
Breast Cancer
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
89
Clinical Trials associated with Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
NCT06522919 / Not yet recruitingPhase 2
Sequential Immunochemotherapy Treatment With Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil (FTD/TPI) Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer (CombiCoR-Vax)
NCT06459024 / Not yet recruitingNot Applicable
Master Framework For Relapse or Refractory Acute Myeloid Leukemia- IMPACT STREAM - A Prospective Observational Study of Treatment Outcomes
NCT06390241 / RecruitingPhase 1
Avidination for Radionuclide THerapy (A.R.THE.) in Nonpalpable Breast Cancer
100 Clinical Results associated with Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Login to view more data
0 Patents (Medical) associated with Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Login to view more data
100 Deals associated with Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Login to view more data
100 Translational Medicine associated with Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori SRL
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
Phase 1 Clinical
Phase 2 Clinical
2
2
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free